Today, we're joined by Duane Boise, CEO of MMJ Holdings, a biopharmaceutical company advancing cannabis-derived medicines through the FDA's botanical Drug Development Pathway. MMJ has received Orphan drug designation for Huntington's disease and multiple sclerosis, and its cannabis-derived soft-gel formulations are now preparing to enter phase 2 clinical trials, helping pave the way for a new era of FDA-validated cannabis medicine.
Duane shares the long road to reaching this milestone, the challenges of bringing cannabis-based therapeutics through the FDA process, and what the future may hold for cannabis as a mainstream medicine.
https://mmjih.com
https://www.linkedin.com/in/duane-boise-b174b9168/